Related Experiment Video
Updated: Jun 18, 2025

The Synthesis, Characterization and Reactivity of a Series of Ruthenium N-triphosPh Complexes
Published on: April 10, 2015
Antimetastatic activity of (arene)ruthenium(II) complex of 4-aryl-4H-naphthopyran
Jitka Pracharova1, Tereza Cyrikova1, Michal Berecka1
1Department of Biophysics, Faculty of Science, Palacky University, CZ-77900, Olomouc, Czech Republic.
Abstract:
Metastatic cancer remains a formidable challenge in anticancer therapy. Despite efforts to develop effective antimetastasis drugs over the past half-century, currently approved treatments fall short of expectations. This report highlights the promising antiproliferative activity of a ruthenium-based therapeutic agent, namely dichlorido(p-cymene)[2-amino-4-(pyridin-3-yl)-4H-benzo[h]-chromene-3-carbonitrile]ruthenium(II) (complex 1) against metastatic cell lines. Complex 1 shows significant efficacy in metastatic LoVo and Du-145 cell lines at nanomolar concentrations, being markedly more active than clinically used anticancer cisplatin. Studies on the MDA-MB-231 cell line, which displays invasive characteristics, demonstrated that 1 significantly reduces cell invasion. This efficacy was confirmed by its impact on matrix metalloproteinase production in MDA-MB-231 cells. Given that cell migration drives cancer invasion and metastasis, complex 1's effect on MDA-MB-231 cell migration was evaluated via wound healing assay and vimentin network analysis. Results indicated a strong reduction in migration. A re-adhesion assay further demonstrated that 1 significantly lowers the re-adhesion ability of MDA-MB-231 cells compared to cisplatin. To better simulate the human body environment, a 3D spheroid invasion assay was used. This method showed that 1 effectively inhibits tumor spheroids from infiltrating the surrounding extracellular matrix. This study underscores the potential of (arene)ruthenium(II) complexes with naphthopyran ligands as potent antimetastatic agents for chemotherapy.
Insights
A novel ruthenium complex demonstrates potent antimetastasis activity against various cancer cell lines. This agent significantly inhibits cancer cell invasion, migration, and metastasis, offering a promising new avenue for chemotherapy.
Area of Science:
- Medicinal Chemistry
- Cancer Biology
- Pharmacology
Background:
- Metastatic cancer presents a significant therapeutic challenge, with limited efficacy of current antimetastasis drugs.
- Developing novel agents to combat cancer metastasis is crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the antimetastatic potential of a ruthenium-based complex, dichlorido(p-cymene)[2-amino-4-(pyridin-3-yl)-4H-benzo[h]-chromene-3-carbonitrile]ruthenium(II) (complex 1).
- To compare the efficacy of complex 1 with cisplatin in preclinical models of metastasis.
Main Methods:
- In vitro antiproliferative assays on metastatic LoVo, Du-145, and MDA-MB-231 cell lines.
- Assessment of cell invasion, matrix metalloproteinase production, cell migration (wound healing, vimentin network analysis), and cell re-adhesion.
- 3D spheroid invasion assay to evaluate inhibition of extracellular matrix infiltration.
Main Results:
- Complex 1 exhibited significant antiproliferative activity against metastatic cell lines at nanomolar concentrations, outperforming cisplatin.
- Complex 1 markedly reduced cell invasion, migration, and re-adhesion in MDA-MB-231 cells.
- The 3D spheroid assay confirmed complex 1's ability to inhibit tumor spheroid invasion of the extracellular matrix.
Conclusions:
- Ruthenium(II) complexes with naphthopyran ligands, such as complex 1, show considerable promise as potent antimetastatic agents.
- Complex 1 represents a potential new therapeutic strategy for managing metastatic cancer.
- Further investigation into (arene)ruthenium(II) complexes is warranted for developing novel chemotherapy treatments.
More Related Videos
Related Concept Videos
ortho–para-Directing Activators: –CH3, –OH, –⁠NH2, –OCH3
Nucleophilic Aromatic Substitution: Addition–Elimination (SNAr)
The reaction begins with an attack of the nucleophile on the carbon that holds the leaving group. This results in the delocalization of the π electrons over the ring carbons. The resonance interaction between...
Physical Properties of Amines
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
meta-Directing Deactivators: –NO2, –CN, –CHO, –⁠CO2R, –COR, –CO2H
Diazonium Group Substitution: –OH and –H

